eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc.
Your view on EFTR
Overview
What the company does, where it operates, and who runs it.
About eFFECTOR Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Davide Ruggero
- Headquarters
- 142 North Cedros Avenue, Solana Beach, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Davide Ruggero
- Headquarters
- 142 North Cedros Avenue, Solana Beach, CA, US
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.
Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E.
eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for eFFECTOR Therapeutics, Inc., and the rating behind it. EFTR last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for eFFECTOR Therapeutics, Inc.. Starting points for eFFECTOR Therapeutics, Inc.: EPS -$16.37, beta 0.98 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for eFFECTOR Therapeutics, Inc.. eFFECTOR Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for eFFECTOR Therapeutics, Inc.. Trailing twelve-month EPS for eFFECTOR Therapeutics, Inc. stands at -$16.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for eFFECTOR Therapeutics, Inc.. eFFECTOR Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
eFFECTOR Therapeutics, Inc. valued side by side against its closest peers. eFFECTOR Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold eFFECTOR Therapeutics, Inc., and how their positions are changing. At a $941 market value, institutional positions materially move eFFECTOR Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by eFFECTOR Therapeutics, Inc. executives and directors. Shares of eFFECTOR Therapeutics, Inc. have traded between $0.0002 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming eFFECTOR Therapeutics, Inc.. eFFECTOR Therapeutics, Inc. is a $941 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming eFFECTOR Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for eFFECTOR Therapeutics, Inc.. Coverage tracks eFFECTOR Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.